MILREM-ROBOTICS
25.11.2021 09:02:10 CET | Business Wire | Press release
The iMUGS Consortium, in charge of a 32,6 MEUR project developing the European standard unmanned ground system (UGS), demonstrated how defence forces can use tactical 4G/5G communications networks and UGS’ equipped with ISR and signal intelligence payloads, jammers, acoustic sensors, and various other technology to conduct missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005387/en/
The demonstration that was performed in September in Latvia, was led by LMT, a member of the integrated Modular Unmanned Ground System (iMUGS) consortium, with the support of the project coordinator Milrem Robotics and featured an ensemble of different technology.
Latvian National Armed Forces used two Milrem Robotics’ THeMIS Unmanned Ground Vehicles (UGV) during two scenarios to display the benefits of teaming up manned units with unmanned systems.
One THeMIS UGV was equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT) provided by The Electronic Communications Office of Latvia, Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios (Tough SDR Vehicular), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The RWS integration was part of the demonstration, but not of the iMUGS project itself.
The second THeMIS, used as a mule for transporting the squad’s equipment, was equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular.
The units and UGVs used Bittium’s tactical communication network TAC WIN combined with LMT’s commercial 4G and a tactical 5G-SA bubble provided by Bittium and Cumucore.
In addition, Krauss-Maffei Wegmann’s (KMW) Dingo infantry mobility vehicle was used as the command centre from where UGVs were operated in Line of Sight (LOS) and Beyond the Line of Sight (BLOS) mode using Bittium’s SDR radios and to where the ISR and Signal Intelligence sensor feed was relayed and incorporated into LMT’s Battle Management System Viedsargs.
“The displayed scenarios showed that unmanned systems, enhanced with innovative communication systems and various defence technology, can be used for collecting and sharing tactical information, improve situational awareness, decrease troops physical load, and increase force protection,” explained Kuldar Väärsi, CEO of Milrem Robotics.
''For the first time ever, in a special network, a tactical network was connected with a stand-alone 5G network. This allowed communication between units and robots, as well as collecting information from sensors and placing this information into LMT’s Battle Management System "Viedsargs'','' said Ingmars Pukis, Vice President and Member of the Management Board of LMT.
Additional equipment used in the demonstration included: SRC Brasa's NATRIX UGV used for CASEVAC, high-speed First-Person View drone, Vertical Take-off, and Landing UAV STAR, and a gunshot detection and source recognition audio sensor by Riga Technical University (RTU).
The iMUGS project was launched in 2020 to develop a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems. Its goal is to standardize a Europe-wide ecosystem for ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will use an existing UGV – Milrem Robotics’ THeMIS – and a specific list of payloads.
The project’s progress is displayed during six demonstrations. „So far Milrem Robotics and LMT Innovations have set the bar very high. Which means we have some great things to wait for as the main results of the iMUGS projects are yet to be seen,“ said Martin Jõesaar from the Estonian Center for Defence Investments, the representative of the participating Member States in the iMUGS Project. The next demonstration will take place in Q1 of 2022 in Finland.
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Bittium, Diehl Defence, dotOcean, GMV Aerospace and Defence, Insta Advance, Krauss-Maffei Wegmann, Latvijas Mobilais Telefons (LMT), NEXTER Systems, Royal Military Academy of Belgium, Safran Electronics & Defense, Sol.One and Talgen Cybersecurity.
Watch the Demo 2 Scenarios here:
https://www.youtube.com/watch?v=-_iLCV3Ob2I
https://www.youtube.com/watch?v=HbK_ixrTuWU
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005387/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom